Viridian Therapeutics (NASDAQ:VRDN) Given New $27.00 Price Target at The Goldman Sachs Group

Viridian Therapeutics (NASDAQ:VRDN) had its price objective decreased by The Goldman Sachs Group from $31.00 to $27.00 in a research note released on Wednesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

A number of other brokerages have also recently commented on VRDN. Needham & Company LLC decreased their price objective on Viridian Therapeutics from $38.00 to $36.00 and set a “buy” rating for the company in a research note on Wednesday. JMP Securities lowered their price target on Viridian Therapeutics from $42.00 to $38.00 and set a “market outperform” rating for the company in a research note on Wednesday. HC Wainwright reissued a “buy” rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. Finally, Royal Bank of Canada cut their target price on shares of Viridian Therapeutics from $46.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, Viridian Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.70.

Viridian Therapeutics Stock Performance

Viridian Therapeutics stock opened at $12.54 on Wednesday. Viridian Therapeutics has a 1 year low of $9.90 and a 1 year high of $27.20. The company’s 50-day moving average is $13.71 and its two-hundred day moving average is $17.53. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.02 billion, a PE ratio of -2.91 and a beta of 0.57.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.08. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.16 million. The firm’s quarterly revenue was up .0% compared to the same quarter last year. Equities analysts anticipate that Viridian Therapeutics will post -4.03 earnings per share for the current year.

Hedge Funds Weigh In On Viridian Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. R Squared Ltd bought a new position in shares of Viridian Therapeutics in the 4th quarter valued at about $26,000. Amalgamated Bank lifted its position in shares of Viridian Therapeutics by 49.7% in the first quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock valued at $34,000 after buying an additional 840 shares during the last quarter. Foresite Capital Management VI LLC acquired a new position in shares of Viridian Therapeutics during the 4th quarter worth approximately $38,000. AlphaQuest LLC raised its stake in Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after acquiring an additional 1,519 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in Viridian Therapeutics by 3,892.9% during the 1st quarter. GAMMA Investing LLC now owns 8,425 shares of the company’s stock valued at $114,000 after purchasing an additional 8,214 shares during the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.